OCGN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Ocugen Inc (OCGN) is not a strong buy for a beginner investor with a long-term strategy at this time. While the company has shown improvements in financial performance and has a positive catalyst with the appointment of a new CFO, the technical indicators are neutral, and there are no strong trading signals or significant options activity to suggest immediate upside potential. The stock's recent dilution through a $22.5 million common stock offering and its negative net income remain concerns for long-term investment.
The MACD is below zero and negatively contracting, indicating a bearish trend. RSI is neutral at 44.258, and moving averages are converging, showing no clear directional signal. The stock is trading near its pivot level of 1.419, with resistance at 1.507 and support at 1.331.
The appointment of Rita Johnson-Greene as CFO, leveraging her 20 years of healthcare experience, is a positive development. Revenue increased by 54.23% YoY in Q3 2025, and gross margin remains at 100%.
The company recently announced a $22.5 million common stock offering at $1.50 per share, which could dilute existing shareholder value. Net income remains negative at -$20.05 million, despite YoY improvement.
In Q3 2025, revenue increased by 54.23% YoY to $1.75 million. Net income improved by 54.60% YoY but remains negative at -$20.05 million. EPS improved by 40% YoY to -0.07. Gross margin remains at 100%.
No recent analyst ratings or price target changes are available for OCGN.
